SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-16956"
 

Sökning: id:"swepub:oai:DiVA.org:uu-16956" > C-Peptide replaceme...

C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

Ekberg, Karin (författare)
Brismar, Tom (författare)
Karolinska Institutet
Johansson, Bo-Lennart (författare)
visa fler...
Lindström, Per (författare)
Juntti-Berggren, Lisa (författare)
Karolinska Institutet
Norrby, Anders (författare)
Berne, Christian (författare)
Uppsala universitet,Institutionen för medicinska vetenskaper,Endokrinologi, diabetes och metabolism
Arnqvist, Hans, 1943- (författare)
Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Avdelningen för medicinsk cellbiologi,Endokrin- och magtarmmedicinska kliniken US
Bolinder, Jan (författare)
Karolinska Institutet
Wahren, John (författare)
Karolinska Institutet
visa färre...
 (creator_code:org_t)
American Diabetes Association, 2007
2007
Engelska.
Ingår i: Diabetes Care. - : American Diabetes Association. - 0149-5992 .- 1935-5548. ; 30:1, s. 71-76
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • OBJECTIVE - C-peptide replacement in animals results in amelioration of diabetes-induced functional and structural abnormalities in peripheral nerves. The present study was undertaken to examine whether C-peptide administration to patients with type 1 diabetes and peripheral neuropathy improves sensory nerve function. RESEARCH DESIGN AND METHODS - This was an exploratory, double-blinded, randomized, and placebo-controlled study with three study groups that was carried out at five centers in Sweden. C-peptide was given as a replacement dose (1.5 mg/day, divided into four subcutaneous doses) or a dose three times higher (4.5 mg/day) during 6 months. Neurological examination and neurophysiological measurements were performed before and after 6 months of treatment with C-peptide or placebo. RESULTS - The age of the 139 patients who completed the protocol was 44.2 ± 0.6 (mean ± SE) years and their duration of diabetes was 30.6 ± 0.8 years. Clinical neurological impairment (NIA) (score >7 points) of the lower extremities was present in 86% of the patients at baseline. Sensory nerve conduction velocity (SCV) was 2.6 ± 0.08 SD below body height-corrected normal values at baseline and improved similarly within the two C-peptide groups (P < 0.007). The number of patients responding with a SCV peak potential improvement >1.0 m/s was greater in C-peptide-treated patients than in those receiving placebo (P < 0.03). In the least severely affected patients (SCV < 2.5 SD below normal at baseline, n = 70) SCV improved by 1.0 m/s (P < 0.014 vs. placebo). NIA score and vibration perception both improved within the C-peptide-treated groups (P < 0.011 and P < 0.002). A1C levels (7.6 ± 0.1% at baseline) decreased slightly but similarly in C-peptide- and placebo-treated patients during the study. CONCLUSIONS - C-peptide treatment for 6 months improves sensory nerve function in early-stage type 1 diabetic neuropathy.

Nyckelord

MEDICINE
MEDICIN

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy